David Shaw’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

David Shaw’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,580	Closed	-$1.23M	–	4397
2020 Q1	$1.23M	Buy	+25,580	New	+$1.19M	﹤0.01%	2580
2019 Q4	–	Sell	-157,655	Closed	-$6.97M	–	4271
2019 Q3	$3.73M	Sell	157,655 -259,215	-62%	-$7.68M	﹤0.01%	1871
2019 Q2	$12.5M	Sell	416,870 -121,976	-23%	-$2.79M	0.02%	1012
2019 Q1	$12.1M	Buy	538,846 +291,604	+118%	+$6.27M	0.02%	990
2018 Q4	$4.5M	Buy	247,242 +141,395	+134%	+$2.22M	0.01%	1580
2018 Q3	$1.92M	Buy	105,847 +84,227	+390%	+$998K	﹤0.01%	2226
2018 Q2	$215K	Buy	+21,620	New	+$149K	﹤0.01%	3530
2017 Q4	–	Sell	-28,563	Closed	-$417K	–	3827
2017 Q3	$417K	Buy	28,563 +6,807	+31%	+$103K	﹤0.01%	3005
2017 Q2	$408K	Sell	21,756 -16,088	-43%	-$363K	﹤0.01%	2898
2017 Q1	$806K	Sell	37,844 -3,556	-9%	-$68K	﹤0.01%	2452
2016 Q4	$629K	Buy	+41,400	New	+$563K	﹤0.01%	2727

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

David Shaw's RARX Position: Q2 2020 in Review

David Shaw sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 25,580 shares — an estimated $1.23M sold.

David Shaw first reported a position in RARX in Q4 2016 and held it in 11 quarters. The position peaked at $12.5M in Q2 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

David Shaw reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
David Shaw sold 25,580 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.23M.
David Shaw first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 11 quarters.
David Shaw's Ra Pharmaceuticals, Inc. Common Stock position peaked at $12.5M in Q2 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on D.E. Shaw & Co's 13F filing for Q2 2020, filed 14 Aug 2020.